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Abstract
Background: In drug-refractory heart failure, cardiac resynchronization therapy (CRT) is
an established method in patients with sinus rhythm, severe reduced ejection fraction and
broad QRS. Heart failure is known as a predisposition for atrial fibrillation (AF). However,
the putative impact of atrioventricular node (AVN) ablation in chronic AF and CRT remains
unclear. The aim of this study was to elucidate the effects of CRT in patients with chronic AF
and the requirement for AVN ablation.
Methods: A total of 100 patients were included in the retrospective study, 64 with sinus
rhythm (SR) and 36 with chronic AF with a mean duration of 2.8 ± 0.5 years. Clinical
parameters, QRS duration and echocardiographic parameters were compared at baseline and
after a follow-up of 11 ± 0.34 months in patients with SR and in 27 patients with chronic AF
who received optimized medication to control ventricular rate and nine patients who under-
went an AVN ablation.
Results: Baseline characteristics between patients with SR or AF in the presence or absence
of AVN ablation were comparable. In each group, a significant improvement of NYHA class,
ejection fraction could be observed, with an analogous reduction of QRS duration and a dimin-
ished left ventricular end-diastolic dimension after 11 ± 0.34 months of CRT.
Conclusions: The present results demonstrate a comparable improvement in left ventricular
function and functional capacity in all treated groups. In conclusion, AVN ablation is not
a prerequisite for CRT in patients with severe heart failure and chronic AF. (Cardiol J 2009;
16, 3: 246–249)
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Introduction
Cardiac resynchronization therapy (CRT) is an
established method for drug-refractory heart failure
in patients with severe reduced ejection fraction and
broad QRS configuration [1, 2]. Most clinical
studies deal with CRT in patients with sinus
rhythm [1–4]. On the other hand, heart failure predi-
sposes the development of atrial fibrillation (AF)
by atrial dilatation, structural changes in the my-
ocardium and activation of the neuro-hormonal
system [5].
The prevalence of AF in patients with heart
failure varies between 10% and 25% for New York
Heart Association (NYHA) class II to III and appro-
ximately 50% in NYHA class IV [6]. There is gro-
wing evidence that the benefit of CRT in patients
with chronic AF and heart failure is similar to that in
patients with sinus rhythm [7]. Effective suppres-
sion of rapid intrinsic atrio-ventricular conduction
in patients with AF is mandatory to prevent incom-
plete biventricular capture and inhibition of CRT.
It is well known that pharmacological treatment to
control ventricular rate may be sufficient in patients
with AF of short duration or with paroxysmal AF
[8]. However, the putative improvement of atrio-
ventricular node (AVN) ablation versus pharmaco-
logic therapy in chronic AF and biventricular resyn-
chronization therapy remains unclear.
The aim of this present study was to elucidate
the effects of CRT in patients with chronic AF and
the requirement of AVN ablation, comparing clini-
cal and echocardiographic results.
Methods
A total of 100 patients were included in the
retrospective study, 64 with sinus rhythm (SR),
36 with chronic AF with a mean duration of 2.8 ±
± 0.5 years. All patients suffered from drug-refrac-
tory heart failure with NYHA class III–IV, left ven-
tricular ejection fraction (LVEF) < 35%, QRS du-
ration > 120 ms and left bundle branch block. Each
patient had a left ventricular pacing lead in the la-
teral or posterolateral vein region, in the high
right atrium and in the right ventricle. All patients
were on an optimal medical heart failure regime.
To produce a pharmacological blockade of atrio-
ventricular conduction in AF, beta-blockers, digo-
xin and amiodarone were used, in order to ensure
biventricular stimulation and regular left ventricu-
lar contraction. Two thirds of patients with chro-
nic atrial fibrillation had a medication with amio-
darone (Table 1).
Retrospective follow-up and clinical evaluation
were performed after 11 ± 0.34 months. The NYHA
classification of heart failure symptoms was used.
NYHA class, QRS duration and echocardiographic
parameters were compared in patients with SR
(group 1, n = 64) and in 27 patients (group 2) with
chronic AF who received optimized medication to
control ventricular rate, thus resulting in adequate
delivery of biventricular pacing (biventricular sti-
mulation > 90%) and nine patients (group 3) who
underwent an AVN ablation.
The study was approved by the local bioethi-
cal committee and all patients gave their informed
consent.
Statistical analysis
All data are given as means ± standard error
of the mean (SEM). Data were compared with Stu-
dent’s t test for paired and unpaired data. Simulta-
neous comparisons between groups were carried
out by means of one-way analysis of variance follo-
wed by Bonferroni’s post hoc test when three or
more groups were compared. For all tests, a p va-
lue < 0.05 was considered statistically significant.
Results
The study population comprised 64 patients
with SR, 27 patients with chronic AF and nine pa-
tients with AVN ablation, a total of 86 men and
14 women (mean age 70 ± 7 years). The underly-
ing disease was ischemic cardiomyopathy in 68 pa-
tients and nonischemic (dilatative) cardiomyopathy
in 32 patients. Baseline characteristics between pa-
tients with SR or AF in the presence or absence of
AVN ablation were comparable, whereas patients
Table 1. Basal characteristics in patients with
chronic atrial fibrillation (AF) and chronic AF with
atrioventricular node ablation (AVNA). There
were no significant changes of medical heart
failure regime over the follow-up of 11 ± 0.34
months. There was also no significant difference
in medical treatment between the two groups.
AF AF with AVNA
(n = 36) (n = 9)
ACE inhibtor 34 (94%) 8 (89%)
Beta-blocker 35 (97%) 8 (89%)
Diuretic 27 (75%) 9 (100%)
Spironolactone 12 (33%) 3 (33%)
Amiodarone 13 (36%) 1 (11%)
Digoxin 19 (53%) 4 (44%)
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with AF had significant larger left atrial dimensions.
In patients with SR (group 1) mean NYHA class de-
creased from 3.1 ± 0.1 to 1.9 ± 0.1 (p < 0.01) and
QRS duration decreased from 171.9 ± 3.7 ms to
146.3 ± 3.7 ms (p < 0.01) after 11 ± 0.34 months of
CRT. Left ventricular ejection fraction increased
significantly from 24.6 ± 1.1% to 34.7 ± 1.4% (p < 0.01)
and left ventricular end-diastolic dimension
(LVEDD) decreased from 67.8 ± 1.1 mm to 61.4 ±
± 1.3 mm (p < 0.01) during follow up (Table 2).
In patients with chronic AF (group 2), mean
NYHA class decreased from 3.2 ± 0.1 to 2.2 ± 0.1
(p < 0.01). The broad QRS decreased from 189.5 ±
± 5.2 ms to 156.7 ± 3.5 ms (p < 0.01). After
11 ± 0.34 months of CRT the LVEF augmented from
23.7 ± 1.2% to 40.0 ± 1.8% (p < 0.01) and LVEDD
diminished from 69.7 ± 1.5 mm to 62.9 ± 1.4 mm
(p < 0.05) (Table 2).
In patients with chronic AF who had AVN abla-
tion (group 3), mean NYHA class (3.2 ± 0.1 vs. 2.3 ±
± 0.2; p < 0.01), QRS duration (177.8 ± 6.8 ms vs.
134.4 ± 5.2 ms; p < 0.05) and LVEDD (66.3 ± 1.9 mm
vs. 56.2 ± 2.1 mm; p < 0.05) decreased in response
to CRT in a comparable manner to the group with
AF and pharmacological treatment. There was also an
analogous improvement in LVEF (24.4 ± 2.7% vs.
37.9 ± 3.4%; p < 0.05) after 11 ± 0.34 months of
CRT (Table 2).
In the AF group with and without AVN abla-
tion, left atrial dimensions were larger as in the SR
group. There was no significant alteration in left
atrial size in patients with SR (45.9 ± 0.8 mm vs.
42.9 ± 0.9 mm) or AF with (52.1 ± 2.3 mm vs. 51.4 ±
± 2.3 mm) or without (52.0 ± 1.0 mm vs. 49.9 ±
± 1.3 mm) AVN ablation after CRT treatment.
Discussion
In this study we assessed the role of CRT in
patients with chronic AF and the requirement of
AVN ablation, comparing clinical and echocardiogra-
phic results.
The benefits of CRT in respect of NYHA class
and LVEF improvement as well as reduction of
QRS duration and LVEDD after follow-up of 11 ±
± 0.34 months were comparable. These findings are
in accordance with previous results showing an im-
provement in clinical and echocardiographic parame-
ters in patients with drug-refractory heart failure
and CRT [1–6]. Recent studies have been almost
exclusively restricted to patients with stable sinus
rhythm [1–4]. However, the prevalence of AF in
patients with heart failure and NYHA class II to IV
varies between 25% and 50% [6]. There is growing
evidence that the benefit in patients with chronic
AF and heart failure is similar to that in patients with
sinus rhythm [7]. A few studies have shown an acute
improvement in hemodynamic response in patients
with chronic AF immediately after CRT [9, 10]. The
role of AVN ablation in patients with chronic AF
versus optimal pharmacological treatment remains
unclear. Recent results suggest a pharmacological
therapy to control ventricular rate may be sufficient
in patients with AF of short duration or paroxysmal
AF [6]. Our study indicates a benefit and improve-
ment of clinical parameters (NYHA) as well as echo-
cardiographic results (LVEF, LVEDD) of CRT also
in patients with chronic AF with a mean duration of
2.8 ± 0.5 years, but CRT had no effect on enlarged
atrial dimensions in patients with AF with or
without AVN ablation.
Our results accord with data from Molhoek et al.
[11] who demonstrated a comparable benefit from
CRT in patients with chronic AF compared to those
who had SR. Corresponding data from Dorszewski
et al. [12] showed a comparable improvement over
a long-term follow-up in left ventricular function
and exercise capacity in patients with chronic AF
and optimized medical treatment. In contrast,
results from Gasparini et al. [13] suggested a high
Table 2. Characteristics of patients with sinus rhythm (SR), chronic atrial fibrillation (AF) and chronic AF
with atrioventricular node ablation (AVNA) at baseline and after a follow-up of 11 ± 0.34 months.
All data are given as means ± standard error of the mean (SEM).
SR (n = 64) AF (n = 27)                       AF with AVNA (n = 9)
Baseline Follow-up  Baseline Follow-up Baseline Follow-up
NYHA class 3.1±0.1 1.9±0.1* 3.2±0.1 2.2±0.1†† 3.2±0.1 2.3± 0.2‡
QRS [ms] 171.9±3.7 146.3±3.7* 189.5±5.2 156.7±3.5†† 177.8±6.8 134.4 ± 5.2‡
LVEF (%) 24.6±1.1 34.7±1.4* 23.7±1.2 40.0±1.8†† 24.4±2.7 37.9± 3.4‡
LVEDD [mm] 67.8±1.1 61.4±1.3* 69.7±1.5 62.9±1.4† 66.3±1.9 56.2± 2.1‡
*p < 0.01 versus baseline SR, ††p < 0.01 and †p < 0.05 versus baseline AF, ‡p < 0.05 versus baseline AF with AVNA. Follow-up SR versus follow-up
AF and versus follow-up AF with AVNA; p = non significant; NYHA — New York Heart Association, LVEF — left ventricular ejection fraction, LVEDD
— left ventricular end-diastolic dimension
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percentage of inadequate biventricular capture in
patients with pharmacological treatment in AF and
CRT. In this study, long-term improvements of left
ventricular function and functional capacity were
only observed if AVN ablation was performed. We
achieved an adequate delivery of biventricular pa-
cing (biventricular stimulation > 90%) in patients
who received an optimized medication to control
ventricular rate in chronic AF.
Comparing patients with chronic AF without
AVN ablation against patients with AF who had
AVN ablation, improvement of NYHA class, LVEF
as well as decreased QRS duration and LVEDD
were similar. This suggests that a sufficient rate
control is the successful therapy option for the
majority of patients with chronic AF and indication
for CRT. Therefore, AVN ablation is not a precon-
dition for cardiac resynchronization in patients with
severe heart failure and chronic atrial fibrillation.
Limitations of the study
Several limitations apply to the present study.
First, it had a relatively small sample size. Also, the
precise duration of chronic AF before CRT is un-
known and no data about annual hospitalization and
long-term survival exist.
Conclusions
In conclusion, our results show a comparable
improvement in left ventricular function and func-
tional capacity in all treated groups, whereas an
AVN ablation is not a prerequisite for cardiac
resynchronization in patients with severe heart
failure and chronic AF.
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